Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.

Griffiths, RI; Sullivan, EM; Frank, RG; Strauss, MJ; Herbert, RJ; Clouse, J; Goldman, HH

Abstract:

OBJECTIVE: An analysis of administrative and claims data was performed to compare the resource use and costs to a managed-care organisation of venlafaxine, a serotonin and norepinephrine reuptake inhibitor (SNRI), versus tricyclic antidepressant (TCA) therapy, after switching from a selective serotonin reuptake inhibitor (SSRI). DESIGN: One-year costs and frequencies of all medical services, and of services coded for depression, were compared between patients who received venlafaxine and TCA ...

Expand abstract

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Griffiths, R. I., Sullivan, E. M., Frank, R. G., Strauss, M. J., Herbert, R. J., Clouse, J., & Goldman, H. H. (1999). Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression. PharmacoEconomics, 15(5), 495–505.

MLA Style

Griffiths, R. I., et al. “Medical Resource Use and Cost of Venlafaxine or Tricyclic Antidepressant Therapy. Following Selective Serotonin Reuptake Inhibitor Therapy for Depression.” PharmacoEconomics, vol. 15, no. 5, PharmacoEconomics, 1999, pp. 495–505.

Chicago Style

Griffiths, RI, EM Sullivan, RG Frank, MJ Strauss, RJ Herbert, J Clouse, and HH Goldman. 1999. “Medical Resource Use and Cost of Venlafaxine or Tricyclic Antidepressant Therapy. Following Selective Serotonin Reuptake Inhibitor Therapy for Depression.” PharmacoEconomics 15 (5): 495–505.
Tweet
Print